As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.

A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Drugs like Ozempic and Wegovy have the power to block the forces driving obesity, but the knock-on societal effects may not necessarily be so positive ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Is the era of sourcing cheaper weight loss drugs from the internet over? High demand for GLP-1 agonists — prescription drugs ...

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

Billions of dollars in annual revenue and the health of millions of patients are at stake in a drug industry battle over who ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.